Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875012 | 0.79 | LMNA (0.37) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL17440276 | 0.77 | LMNA (0.35) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL1879166 | 0.73 | ALDH1A1 (0.35) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL1703670 | 0.71 | PKM (0.45) | LMNAHPGDMEN1KMT2ARAB9A | |
| SCHEMBL4410432 | 0.71 | LMNA (0.31) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL1648161 | 0.70 | PTGDR2 (0.36) | ALDH1A1KDM4EGLAHPGDPOLB | |
| SCHEMBL16429292 | 0.70 | TSHR (0.33) | LMNAALDH1A1MAPK1TSHRMEN1 | |
| SCHEMBL1704450 | 0.69 | PKM (0.49) | LMNAALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL28935727 | 0.69 | KDM4E (0.38) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL29048373 | 0.68 | DAO (0.39) | LMNAALDH1A1GAAPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908895-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-9255096-B1 | Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors | ALLERGAN, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | LMNA 4881/4885ALDH1A1 4431/4885KDM4E 819/4885 |
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | LMNA 4881/4885ALDH1A1 4431/4885KDM4E 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.